Companies › Neuboron Bio-SciTech
2 active drug programs in 2 registered trials: 2 Phase 2; Oncology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NBB-001 (BPA) Boron-containing compound for neutron capture therapy | – | Phase 2 | Head and Neck Cancer | Aug 2027 |
| NBB-002 (18F-BPA) Fluorine-18 labeled boron-containing compound for PET imaging and neutron capture therapy | – | Phase 2 | Head and Neck Cancer | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07795034 | NBB-001 (BPA) | Phase 2 | Head and Neck Cancer | Oncology | Aug 2027 |
| NCT07795034 | NBB-002 (18F-BPA) | Phase 2 | Head and Neck Cancer | Oncology | Aug 2027 |
No annotated target.
–
Hangzhou Converd Abscint NV/SA Beijing Gene Key Life Technology Beijing Yongtai Ruike Biotechnology Company CNBG-Virogin Biotech (Shanghai)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.